An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
NCT05131438 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-03-27
Summary
This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
Conditions
- Extranodal NK/T-cell Lymphoma
Interventions
- DRUG
-
sugemalimab
sugemalimab (Anti-PD-L1 antibody)
Sponsors & Collaborators
-
EQRx International, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
NCT05909098 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
NCT00732498 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib for Adult T-Cell Leukemia
NCT01712659 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
NCT03815682 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
NCT05814848 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
NCT00308087 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
NCT07225439 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00112931 ·Status: COMPLETED ·Phase: PHASE3
-
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
NCT01682044 ·Status: COMPLETED ·Phase: PHASE2
-
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
NCT06996132 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL
NCT05050630 ·Status: UNKNOWN ·Phase: PHASE2
-
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
NCT01081808 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
NCT02535286 ·Status: COMPLETED ·Phase: PHASE1
-
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
NCT04989621 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00026182 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 ·Status: COMPLETED ·Phase: PHASE1
-
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
NCT03211065 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
NCT00168727 ·Status: COMPLETED ·Phase: PHASE4
-
Chemotherapy for Participants With Lymphoma
NCT00436280 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
NCT00510471 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma
NCT00347971 ·Status: COMPLETED ·Phase: PHASE1
-
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
NCT06618313 ·Status: RECRUITING ·Phase: NA
-
Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)
NCT01662102 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307267 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3